<?xml version="1.0" encoding="utf-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>: iStockAnalyst.com  Symbols Feed</title>
    <link>http://www.istockanalyst.com</link>
    <description>Custom RSS Feed</description>
    <generator>http://www.iStockAnalyst.com</generator>
    <pubDate>Sun, 08 Nov 2009 12:59:27 GMT</pubDate>
    <language>en</language>
    <ttl>30</ttl>
    <item>
      <title>10 Extreme Trades On Pending Clinical Trial Results</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3232161</guid>
      <description><![CDATA[As a follow-up to my recent article on nine extreme FDA trades of pending new product decisions among small and micro-cap companies, I have examined the BioMedReports.com Clinical Trial Calendar database to find companies with market caps below $250M which have pending Phase 2 or 3 clinical trial results expected before the end of 2009. Below is a sample of 10 stocks meeting this criteria from the database of 111 entries included in the BioMedReports.com Clinical Trial Calendar, which is in addi (...)<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3232161>[More...]</a>]]></description>
      <pubDate>Thu, 14 May 2009 15:37:15 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">ARNA</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">AVNR</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">CLDA</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">FOLD</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">GNTA</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">INSM</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">JAZZ</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">OREX</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">PARD</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">RMTI</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3232161</link>
    </item>
    <item>
      <title>Earnings Preview For Mar 16 - 20</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3116903</guid>
      <description><![CDATA[Guess, Inc. (GES) could top expectations. FedEx Corporation (FDX) could disappoint. Adobe Systems (ADBE), Nike (NKE) and Oracle (ORCL) will also report.            The earnings calendar is limited this week with just 93 companies confirmed to report. First-quarter earnings season will<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3116903>[More...]</a>]]></description>
      <pubDate>Fri, 13 Mar 2009 21:27:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">ABG</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">ADBE</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">AHR</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">AIR</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">ALOT</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">AMC</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">ATU</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">B</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">BBI</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">BKS</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">BLTI</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">BSC</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">CCL</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">CDTI</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">CHRS</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">CKEC</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">CLC</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">CMLS</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">CPBY</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">CPI</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">CPWM</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">CRAI</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">CRYP</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">CSIQ</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">CTAS</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">CTR</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">CVO</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">CYPB</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">DIET</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">DRI</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">DSTI</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">ENG</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">ESC</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">FDS</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">FDX</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">FLDR</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">FTK</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">GES</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">GOL</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">GS</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">GST</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">HWCC</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">ICOP</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">IDT</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">IHS</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">JMBA</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">KCAP</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">KIRK</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">LTON</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">LUB</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">MDV</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">MDVN</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">MLHR</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">MS</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">NEOG</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">NKE</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">NNBR</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">NWY</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">OMN</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">ORBC</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">ORCH</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">ORCL</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">PALM</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">PARD</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">PERY</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">PLCE</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">PLUG</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">PMI</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">PRGS</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">PRSC</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">PRST</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">RDNT</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">SAH</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">SCVL</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">SHS</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">SINA</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">SKIL</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">SMRT</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">SMTS</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">SONC</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">STAA</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">STON</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">STRL</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">TNP</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">TWER</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">UGNE</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">ULTR</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">USHS</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">WGO</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3116903</link>
    </item>
    <item>
      <title>Celgene: Take The Money and Run</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3090935</guid>
      <description><![CDATA[Of all the healthcare companies that took a beating in 2009, Celgene (CELG) seems to be the most undervalued one.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3090935>[More...]</a>]]></description>
      <pubDate>Thu, 05 Mar 2009 00:46:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">ALTH</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">CELG</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">INCY</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">PARD</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">SGEN</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3090935</link>
    </item>
    <item>
      <title>Rigel Pharmaceuticals– Crisis Or Opportunity?</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/2782865</guid>
      <description><![CDATA[The past two weeks were anything but easy for Rigel’s (RIGL) shareholders, who saw their shares crash more than 50%. Rigel started 2008 on the right foot after a 200% jump in a single day last December, following impressive data for the company’s flagship<a href=http://www.istockanalyst.com/article/viewarticle/articleid/2782865>[More...]</a>]]></description>
      <pubDate>Mon, 10 Nov 2008 13:52:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">ABT</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">AGN</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">AMGN</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">CVTX</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">GILD</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">INCY</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">JNJ</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">PARD</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">PFE</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">RIGL</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">ROSG</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">WYE</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/2782865</link>
    </item>
    <item>
      <title>When There Is Blood In The Streets - Buy Biotech</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/2698445</guid>
      <description><![CDATA[History has shown again and again that times like these represent a huge long term buying opportunity. This may be particularly true for the biotech segment that, despite weathering the storm better than other segments, has had its share of price declines. During the past several weeks, great biotech stocks, from small early stage companies to fully commercialized companies have been thrown out of portfolios like bad auction rate securities, but the truth is that the value proposition of most of these biotechs did not change at all, and is not likely to change as a result of market conditions. This is why current prices create the best opportunity to get into the<a href=http://www.istockanalyst.com/article/viewarticle/articleid/2698445>[More...]</a>]]></description>
      <pubDate>Fri, 10 Oct 2008 23:32:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">AMGN</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">ARQL</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">ARRY</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">BBI</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">DNA</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">EXEL</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">GILD</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">IMGN</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">MITI</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">PARD</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">RIGL</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">ROSG</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">SGEN</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">SNTA</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/2698445</link>
    </item>
    <item>
      <title>Another Selloff Hits the Market with Volume Well Below Average</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/2476326</guid>
      <description><![CDATA[The stock market indexes all continue to trend below the 50 day moving average with the 200 day moving average trailing right behind it. This is the most bearish possible scenario for the indexes to be in and looking to go long stocks with the indexes setup like this is just asking for trouble. However, the worst possible other factor is finally being relieved. I was not making money in my shorts recently with the market in this negative position but now my shorts are doing well and even the shorts that I lost due to reversals that were unexpected are doing very well.This just goes back to underline how important it is to have guts. If the stock is breaking down on huge volume, with the indexes in clear downtrends, it makes sense that as long as the stock is within 20% of its old highs as long as the pattern is right then it makes sense to get short. I will be looking to get short as many mining, oil, metal, ag, and other stocks that have been rising since<a href=http://www.istockanalyst.com/article/viewarticle/articleid/2476326>[More...]</a>]]></description>
      <pubDate>Tue, 05 Aug 2008 13:59:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">AAPL</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">AGU</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">BOOM</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">CLF</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">EGHT</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">EMIS</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">GNSS</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">GPIC</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">HRZ</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">JDSU</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">LCAV</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">LMLP</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">MOS</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">NEWP</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">OFI</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">PARD</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">QCOM</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">SQM</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">TASR</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">TRA</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">USNA</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">VRUS</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/2476326</link>
    </item>
    <item>
      <title>Poniard Pharmaceuticals – Platinum Rediscovered  (Part II)</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/2304194</guid>
      <description><![CDATA[Poniard Pharmaceuticals – Platinum Rediscovered (Part II)<a href=http://www.istockanalyst.com/article/viewarticle/articleid/2304194>[More...]</a>]]></description>
      <pubDate>Sun, 22 Jun 2008 16:25:58 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">CELG</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">EXEL</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">GSK</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">PARD</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/2304194</link>
    </item>
    <item>
      <title>Just 18 Stocks To Watch Today!</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/2271781</guid>
      <description><![CDATA[AAPL oh my god 3G is coming..developers conference…blehhhh..STFU you friggin geeks, I covered this stock last week, nothing’s changed<a href=http://www.istockanalyst.com/article/viewarticle/articleid/2271781>[More...]</a>]]></description>
      <pubDate>Mon, 09 Jun 2008 15:40:02 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">AAPL</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">CHP</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">CNEH</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">CYPW</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">END</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">HYHY</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">INO</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">ISPH</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">LBAS</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">NCEY</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">PARD</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">PARL</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">PCYC</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">PTEK</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">ROYL</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">TMR</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">UTSI</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">VSCI</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/2271781</link>
    </item>
    <item>
      <title>Poniard Pharmaceuticals– Platinum Rediscovered (Part I)</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/1975467</guid>
      <description><![CDATA[<a href=http://www.istockanalyst.com/article/viewarticle/articleid/1975467>[More...]</a>]]></description>
      <pubDate>Thu, 29 May 2008 16:49:26 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">ASCO</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">AZN</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">BBI</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">CLDA</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">DNA</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">PARD</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">SNY</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">SPPI</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/1975467</link>
    </item>
    <item>
      <title>Poniard Pharmaceuticals Secures $60 Million Committed Equity Financing Facility</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3426255</guid>
      <description><![CDATA[Poniard Pharmaceuticals, Inc. , a biopharmaceutical company focused on oncology, today announced that it has secured a committed equity financing facility under which it may sell up to $60 million of its registered common stock to Azimuth Opportunity Ltd. over an 18 month period. Poniard is not obligated to utilize any of the $60 million facility and remains free to enter into and consummate other equity and debt financing transactions.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3426255>[More...]</a>]]></description>
      <pubDate>Thu, 20 Aug 2009 10:00:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">PARD</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3426255</link>
    </item>
    <item>
      <title>Poniard Pharmaceuticals Reports Second Quarter 2009 Financial Results and Provides a Corporate Update</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3391693</guid>
      <description><![CDATA[Poniard Pharmaceuticals, Inc. , a biopharmaceutical company focused on oncology, today reported financial results for the second quarter ended June 30, 2009, and provided a corporate update.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3391693>[More...]</a>]]></description>
      <pubDate>Tue, 04 Aug 2009 19:56:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">PARD</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3391693</link>
    </item>
    <item>
      <title>Poniard Pharmaceuticals to Present at Two Upcoming Investor Conferences in August</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3380993</guid>
      <description><![CDATA[Poniard Pharmaceuticals, Inc. , a biopharmaceutical company focused on innovative oncology therapies, today announced that Jerry McMahon, Ph.D., chairman and chief executive officer, is scheduled to provide a corporate overview, including a discussion about the clinical development program for the Company&amp;#39;s lead product candidate, picoplatin, at two upcoming investor conferences:<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3380993>[More...]</a>]]></description>
      <pubDate>Wed, 29 Jul 2009 12:27:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">PARD</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3380993</link>
    </item>
    <item>
      <title>Poniard Pharmaceuticals to Host Second Quarter 2009 Financial Results Conference Call on August 4</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3376521</guid>
      <description><![CDATA[Poniard Pharmaceuticals, Inc. , a biopharmaceutical company focused on oncology, today announced that it will hold a conference call on Tuesday, August 4, 2009 to discuss the Company&amp;#39;s second quarter 2009 results and provide a corporate update. Jerry McMahon, Ph.D., chairman and chief executive officer, Ronald A. Martell, president and chief operating officer, Greg Weaver, senior vice president and chief financial officer and Robert De Jager, M.D., chief medical officer, will host the call beginning at 4:30 p.m. Eastern time . A press release for the second quarter ended June 30, 2009, will be released after markets close on August 4.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3376521>[More...]</a>]]></description>
      <pubDate>Tue, 28 Jul 2009 17:01:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">PARD</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3376521</link>
    </item>
    <item>
      <title>Poniard Pharmaceuticals Announces Positive Cardiac Safety Data From Picoplatin Phase 1 Trial Supporting NDA Filing</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3361955</guid>
      <description><![CDATA[Poniard Pharmaceuticals, Inc. , a biopharmaceutical company focused on innovative oncology therapies, today announced results from a Phase 1 cardiac safety study of picoplatin, a new generation platinum-based chemotherapy agent and the Company&amp;#39;s lead product candidate. The Company worked collaboratively with the U.S. Food and Drug Administration to design this study, which is required for new chemical entities.This study evaluated the cardiac safety of picoplatin by determining its effect on the cardiac QT/QTc interval by using time-matched pharmacokinetics and electrocardiograms . A total of 45 patients with advanced solid malignancies received 150 mg/m2 picoplatin. The trial was conducted at seven clinical sites in the United States. Results showed no clinical cardiac-related events. In addition, no evidence of a clinically relevant trend in any ECG parameter was demonstrated.'With these new picoplatin safety data, we continue to make progress toward our goal of initiating the filing in 2009 of a New Drug Application for picoplatin as a second-line treatment for small cell lung cancer, with approval and commercialization targeted for 2010,' said Robert De Jager, M.D., chief medical officer of Poniard. 'More than 1,100 cancer patients have received picoplatin in clinical studies to date. Additional safety and anticipated efficacy data from our ongoing Phase 3 SPEAR study will provide a strong database to support the NDA filing.&amp;#34;The Company plans to present data from the Phase 1 cardiac safety trial at a medical conference later this year.About PicoplatinPicoplatin is a new generation platinum-based chemotherapy agent that is in clinical development for multiple cancer indications, treatment combinations and by two routes of administration. It is designed to overcome platinum resistance associated with chemotherapy in solid tumors. Study data to date suggest that picoplatin has an improved safety profile relative to existing platinum-based cancer therapies. Results to date suggest that hematologic events are common but manageable. Kidney toxicity and nerve toxicity are less frequent and less severe than is commonly observed with other platinum chemotherapy drugs.Poniard is currently evaluating the efficacy and safety of picoplatin in small cell lung cancer in a pivotal Phase 3 SPEAR trial that is being conducted under a Special Protocol Assessment with the FDA. The Company reached its enrollment target in this international, multi-center, randomized, controlled trial in March 2009. Poniard is also evaluating picoplatin in a Phase 2 clinical trial in patients with colorectal cancer and in a Phase 2 clinical trial in patients with castration-resistant prostate cancer. Oral picoplatin has been evaluated in a Phase 1 clinical trial in solid tumors.About Poniard PharmaceuticalsPoniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. For additional information please visit http://www.poniard.com.This release contains forward-looking statements, including statements regarding the Company&amp;#39;s business objectives and strategic goals, drug development plans, and the potential safety and efficacy of its products in development, and commercialization. The Company&amp;#39;s actual results may differ materially from those indicated in these forward-looking statements based on a number of factors, including risks and uncertainties associated with the Company&amp;#39;s research and development activities; the results of clinical testing; the receipt and timing of FDA and other required regulatory approvals; the market&amp;#39;s acceptance of the Company&amp;#39;s proposed products; the Company&amp;#39;s anticipated operating losses, need for future capital and ability to obtain future funding; competition from third parties; the Company&amp;#39;s ability to preserve and protect intellectual property rights; the Company&amp;#39;s dependence on third-party manufacturers and suppliers; the Company&amp;#39;s lack of sales and marketing experience; the Company&amp;#39;s ability to attract and retain key personnel; changes in technology, government regulation and general market conditions; and the risks and uncertainties described in the Company&amp;#39;s current and periodic reports filed with the Securities and Exchange Commission , including the Company&amp;#39;s Annual Report on Form 10-K for the year ended December 31, 2008 and its Quarterly Report on Form 10-Q for the period ended March 31, 2009. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to update any forward-looking statement to reflect new information, events or circumstances after the date of this release or to reflect the occurrence of unanticipated events. 2009 Poniard Pharmaceuticals, Inc. All Rights Reserved.Poniard and Poniard Pharmaceuticals are trademarks of Poniard Pharmaceuticals, Inc.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3361955>[More...]</a>]]></description>
      <pubDate>Tue, 21 Jul 2009 11:57:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">PARD</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3361955</link>
    </item>
    <item>
      <title>Poniard Pharmaceuticals Appoints Gary A. Lyons to Board of Directors</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3341708</guid>
      <description><![CDATA[Poniard Pharmaceuticals, Inc. , a biopharmaceutical company focused on innovative oncology therapies, today announced the appointment of Gary A. Lyons, to the Company's board of directors. His appointment increases the number of directors on the Poniard board to ten.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3341708>[More...]</a>]]></description>
      <pubDate>Thu, 09 Jul 2009 11:57:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">PARD</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3341708</link>
    </item>
    <item>
      <title>Poniard Pharmaceuticals to Present at the 8th Annual Needham Life Sciences Conference</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3303069</guid>
      <description><![CDATA[Poniard Pharmaceuticals, Inc. , a biopharmaceutical company focused on innovative oncology therapies, today announced that Jerry McMahon, Ph.D., chairman and chief executive officer, will provide a corporate overview at the 8th Annual Needham Life Sciences Conference on Wednesday, June 10 at 2:30 p.m. Eastern Time in New York.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3303069>[More...]</a>]]></description>
      <pubDate>Fri, 05 Jun 2009 12:26:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">PARD</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3303069</link>
    </item>
    <item>
      <title>Poniard Pharmaceuticals Announces Progression-Free Survival Data From Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3303039</guid>
      <description><![CDATA[- New Progression-Free Survival, Disease Control and Neurotoxicity Data To Be Presented at 2009 ASCO Annual Meeting Continue to Support Picoplatin as a Neuropathy-Sparing Alternative to Oxaliplatin for First-Line Treatment of Colorectal Cancer -<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3303039>[More...]</a>]]></description>
      <pubDate>Thu, 28 May 2009 11:58:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">PARD</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3303039</link>
    </item>
    <item>
      <title>Poniard Pharmaceuticals Announces Positive Efficacy and Safety Data From Phase 2 Clinical Trial of Picoplatin in Men With Metastatic Prostate Cancer</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3303038</guid>
      <description><![CDATA[- New Progression-Free Survival Data To Be Presented at 2009 ASCO Annual Meeting Support Further Clinical Development of Picoplatin in Combination with Docetaxel/Prednisone as First-Line Therapy for Metastatic Castration-Resistant Prostate Cancer -<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3303038>[More...]</a>]]></description>
      <pubDate>Thu, 28 May 2009 11:56:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">PARD</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3303038</link>
    </item>
    <item>
      <title>Poniard Pharmaceuticals Files Shelf Registration</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3303001</guid>
      <description><![CDATA[Poniard Pharmaceuticals, Inc. , a biopharmaceutical company focused on oncology, today announced that it has filed a shelf registration statement on Form S-3 with the Securities and Exchange Commission that, when declared effective by the SEC, will allow Poniard from time to time to offer and sell up to $60 million aggregate amount of its common stock, common stock warrants or a combination thereof.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3303001>[More...]</a>]]></description>
      <pubDate>Fri, 15 May 2009 11:55:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">PARD</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3303001</link>
    </item>
    <item>
      <title>Form  4          PONIARD PHARMACEUTICALS,  For: Oct 06  Filed by: MARTELL RON (10K)</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3539798</guid>
      <description><![CDATA[<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3539798>[More...]</a>]]></description>
      <pubDate>Thu, 08 Oct 2009 23:08:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">PARD</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3539798</link>
    </item>
    <item>
      <title>Form  4          WEAVER GREGORY L          For: Aug 21 (10K)</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3429876</guid>
      <description><![CDATA[<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3429876>[More...]</a>]]></description>
      <pubDate>Fri, 21 Aug 2009 17:38:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">PARD</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3429876</link>
    </item>
    <item>
      <title>Form  4          PONIARD PHARMACEUTICALS,  For: Jul 11  Filed by: LYONS GARY A (10K)</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3348721</guid>
      <description><![CDATA[<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3348721>[More...]</a>]]></description>
      <pubDate>Tue, 14 Jul 2009 19:16:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">PARD</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3348721</link>
    </item>
    <item>
      <title>Form  4          PONIARD PHARMACEUTICALS,  For: Jul 07  Filed by: LYONS GARY A (10K)</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3340762</guid>
      <description><![CDATA[<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3340762>[More...]</a>]]></description>
      <pubDate>Thu, 09 Jul 2009 23:43:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">PARD</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3340762</link>
    </item>
    <item>
      <title>Form  3          PONIARD PHARMACEUTICALS,  For: Jul 07  Filed by: LYONS GARY A (10K)</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3340759</guid>
      <description><![CDATA[<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3340759>[More...]</a>]]></description>
      <pubDate>Thu, 09 Jul 2009 23:42:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">PARD</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3340759</link>
    </item>
    <item>
      <title>Form  4          JACKSON MICHAEL K         For: Jun 02 (10K)</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3256231</guid>
      <description><![CDATA[<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3256231>[More...]</a>]]></description>
      <pubDate>Wed, 03 Jun 2009 20:57:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">PARD</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3256231</link>
    </item>
    <item>
      <title>Form  4          BASSO ROBERT S            For: Apr 03 (10K)</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3182289</guid>
      <description><![CDATA[<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3182289>[More...]</a>]]></description>
      <pubDate>Tue, 07 Apr 2009 16:03:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">PARD</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3182289</link>
    </item>
    <item>
      <title>Form  4          PONIARD PHARMACEUTICALS,  For: Apr 06  Filed by: WEAVER GREGORY L (10K)</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3179713</guid>
      <description><![CDATA[<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3179713>[More...]</a>]]></description>
      <pubDate>Mon, 06 Apr 2009 19:49:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">PARD</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3179713</link>
    </item>
    <item>
      <title>Form  4          PONIARD PHARMACEUTICALS,  For: Mar 27  Filed by: CRAVES FRED B (10K)</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3158598</guid>
      <description><![CDATA[<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3158598>[More...]</a>]]></description>
      <pubDate>Mon, 30 Mar 2009 18:41:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">PARD</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3158598</link>
    </item>
    <item>
      <title>Form  4          PONIARD PHARMACEUTICALS,  For: Mar 26  Filed by: CRAVES FRED B (10K)</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3158592</guid>
      <description><![CDATA[<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3158592>[More...]</a>]]></description>
      <pubDate>Mon, 30 Mar 2009 18:39:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">PARD</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3158592</link>
    </item>
    <atom:link href="http://www.istockanalyst.com/widget/customsymbolfeed.aspx?symbols=PARD" rel="self" type="application/rss+xml" />
  </channel>
</rss>